The label dose, the half-life behind it, and how the program arrived at 1.75 mg

The FDA-approved regimen

The bremelanotide US label specifies a single 1.75 mg subcutaneous injection administered in the abdomen or thigh via a single-dose disposable autoinjector, taken as-needed at least 45 minutes before anticipated sexual activity ^[9].

Two additional limits apply: no more than one dose in any 24-hour period, and no more than eight doses in any 28-day period ^[9][11]. The 24-hour rule reflects pharmacokinetic clearance and the transient pressor effect (see below). The eight-per-month cap reflects the focal-hyperpigmentation risk that rises with cumulative MC1R exposure ^[11].

The label is explicit that the optimal duration of use has not been established and that the drug should be discontinued after eight weeks if a patient does not report improvement ^[9]. Bremelanotide is indicated only for premenopausal women with acquired, generalized HSDD; the label does not support use in postmenopausal women, in men, or for sexual enhancement in individuals without HSDD.

Pharmacokinetics that shape the schedule

The 1.75 mg subcutaneous dose produces a mean Cmax of 77.1 ng/mL, a median Tmax of approximately 1.0 hour, and a terminal half-life of approximately 2.7 hours (range 1.9-4.0 h) ^[9]. Bioavailability by the subcutaneous route is essentially complete (~100%), with 21% serum protein binding, mean clearance of 6.5 L/h, and volume of distribution 25 L. Elimination is approximately 65% renal and 23% fecal ^[9].

The short plasma half-life is the pharmacologic argument for as-needed rather than chronic daily dosing. Onset of pharmacologic effect typically occurs within 45-60 minutes of injection — the basis for the label's 45-minute pre-activity recommendation — while self-reported desire benefit and central neuroimaging effects have been measurable for up to 24 hours after a single dose ^[5][9]. There is no labeled titration schedule and no labeled maintenance regimen: the on-demand schedule is the regimen.

Historical dose-finding: how 1.75 mg was chosen

The dose used in the RECONNECT pivotal trials was selected through earlier Phase 1 and Phase 2 dose-ranging work that explored 0.3 to 10 mg subcutaneous doses ^[9][19]. The 1.75 mg dose emerged as the best balance of efficacy on desire-domain endpoints and tolerability — particularly nausea, flushing, and transient blood-pressure increase, all of which scale with dose.

Early intranasal work in male ED populations used a different dose range. The original Diamond 2004 study evaluated 4, 7.5, 10, 15, and 20 mg intranasal doses, finding a dose-dependent, statistically significant pro-erectile response above the 7 mg threshold ^[7]. The subsequent combination study with sildenafil used 7.5 mg intranasal plus 25 mg oral sildenafil ^[8]. Neither intranasal dose forms part of the current label — the intranasal route was discontinued after blood-pressure signals at higher doses prompted a route change to subcutaneous ^[19].

The rat behavioral work that supplied the original behavioral rationale used 50, 100, and 200 μg/kg subcutaneous doses in ovariectomized Long-Evans females ^[6]. These are research-context doses; they do not translate directly to human dosing and are summarized here only for completeness.

The two-rule cap, in clinical context

Two label rules govern the cumulative exposure ceiling. The 24-hour minimum interval between doses is supported by the pharmacokinetic clearance profile (drug essentially gone by 12-15 hours but the cardiovascular safety window extends through the same interval) and by the transient pressor effect, which adds approximately +3/+2 mmHg within two hours of dosing and resolves within 8-12 hours ^[10].

The eight-doses-per-28-days cap addresses a different risk. Focal hyperpigmentation — discrete darkening of skin, gums, or breasts — was reported in approximately 1% of bremelanotide-treated patients in Phase 3 trials, and risk rose with more than eight doses per 28-day period ^[11]. The mechanism is MC1R activation on cutaneous melanocytes — a predictable consequence of non-selective melanocortin agonism that the linear-MSH derivatives have always carried — and the pigmentation may be incompletely reversible on discontinuation, which is the reason it sits at the heart of the dose-cap math.

Contraindications and label warnings worth restating

The label contraindicates bremelanotide in patients with uncontrolled hypertension or known cardiovascular disease, and recommends against use in patients at high cardiovascular risk (smoking, diabetes, obesity, dyslipidemia, age) ^[10]. Blood pressure should be well controlled before initiation and reassessed periodically during use.

The label notes drug-drug interactions with naltrexone (bremelanotide may decrease naltrexone exposure to subtherapeutic levels in patients receiving naltrexone for opioid- or alcohol-use disorder) and with orally-administered drugs whose absorption depends on rapid gastric emptying ^[9]. The drug should be discontinued after eight weeks without improvement.

A single LiverTox-reported case of acute hepatitis with full recovery on discontinuation has been described; the LiverTox likelihood score is D (possible rare cause). Pregnancy and lactation status are addressed in the label; the drug is not indicated in postmenopausal women or in men, and there is no labeled pediatric indication.